Thr295
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr295  -  PKCD (human)

Site Information
AEALNQVtQRAsRRs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4272376
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 , 4 , 5 , 6 ) , phospho-antibody ( 2 ) , western blotting ( 2 )
Disease tissue studied:
breast cancer ( 5 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , leukemia ( 6 ) , acute myelogenous leukemia ( 6 ) , lung cancer ( 3 , 4 , 5 ) , non-small cell lung cancer ( 3 , 5 ) , non-small cell lung adenocarcinoma ( 3 , 4 ) , non-small cell large cell lung carcinoma ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Kinases, in vitro:
PKCD (human) ( 2 , 7 )

Downstream Regulation
Effects of modification on PKCD:
enzymatic activity, induced ( 7 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Gong J, et al. (2015) The C2 Domain and Altered ATP-Binding Loop Phosphorylation at Ser³⁵⁹ Mediate the Redox-Dependent Increase in Protein Kinase C-δ Activity. Mol Cell Biol 35, 1727-40
25755284   Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

5

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

6

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

7

Rybin VO, et al. (2009) Regulatory autophosphorylation sites on protein kinase C-delta at threonine-141 and threonine-295. Biochemistry 48, 4642-51
19366211   Curated Info